Skip to content

Ionis Pharmaceuticals IONS Operating Segments — Royalty Revenue

Discontinued — last reported Q4 '17

Similar metrics at other companies

Biogen logo
BIIBRoyalty and other revenue — Total Revenue
$9.7M-11.8%
BridgeBio Pharma logo
BBIORoyalty revenue — Revenue
$9.5M+4,557%
Incyte logo
INCYProduct royalty revenues — Total revenues
$151.19M+15.7%
BridgeBio Pharma logo
BBIORoyalty Revenue — Revenue
$1.62M
Incyte logo
INCYOLUMIANT Royalty Revenues — Total revenues
$36.41M+18.2%
Moderna logo
MRNALicensing and royalty revenue — Total Revenue
$0-100%

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RoyaltyRevenue.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 28, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does operating segments — royalty revenue mean?
Revenue earned by a segment from licensing intellectual property to others.
How do you interpret operating segments — royalty revenue?
Increasing royalty revenue signals successful commercialization of licensed assets by partners.
How does operating segments — royalty revenue compare across companies?
Common in biotech companies that utilize a partnership-heavy business model.